AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Exclusive rights to develop cancer targets acquired.
2003 FEB 5 - (NewsRx.com & NewsRx.net) -- Eos Biotechnology and Aventis Pasteur announced that a 2-year collaboration to identify unique cancer vaccine targets has resulted in Aventis Pasteur exercising its options to develop up to five of these targets.
Under terms of the agreement, Aventis Pasteur is granted the exclusive worldwide rights to develop and commercialize vaccines using these unique targets discovered by Eos Biotechnology.
Using its proprietary technologies and integrated genomics-based approach, Eos analyzed selected cancer tissues and identified intracellular targets that could enable the development of safe and effective cancer vaccines. Aventis Pasteur will apply its recognized expertise and resources to preclinical and clinical development, and to the commercialization of developed products. Eos' own extended therapeutic programs are ...
- Aventis Pasteur Acquires Exclusive Rights to Develop Novel Cancer Targets...
- Press release article from: PR Newswire January 13, 2003 700+ words
...PRNewswire/ -- Eos Biotechnology and Aventis Pasteur today announced that...Director, Cancer for Aventis Pasteur. David Martin, M.D., CEO, Eos Biotechnology said, "We are very pleased that Aventis Pasteur has exercised its...
- AVENTIS PICKS FIVE EOS TARGETS; VACCINE DEAL ENDS WITH 'BANG'.(Aventis Pasteur,...
- Magazine article from: BIOWORLD Today Osborne, Randall January 14, 2003 700+ words
...National Editor Two years after starting their deal for cancer vaccines, Aventis Pasteur has exercised its option to develop up to five targets discovered by Eos Biotechnology Inc., hitting the first major milestone and effectively finishing...
- Eos Biotechnology and Aventis Pasteur Announce Major Genomics-Based Cancer...
- Press release article from: PR Newswire June 6, 2000 700+ words
...PRNewswire/ -- Eos Biotechnology, Inc. has...alliance with Aventis Pasteur, a wholly...collaboration with Aventis Pasteur allows Eos...and CEO of Eos Biotechnology, Inc...229, for Eos Biotechnology, Inc...Simpson of Aventis Pasteur Limited...
- Aventis Pasteur. (Active Pharmaceutical Ingredient Watch).(is working on five...
- Magazine article from: Chemical Market Reporter January 20, 2003 700+ words
AVENTIS PASTEUR is exercising its options to develop up to five targets stemming from a two-year pact with Eos Biotechnology. Under the terms of the deal, Aventis Pasteur is granted the exclusive global rights to develop...
- Eos Biotechnology Announces Termination of Proposed Merger with Pharmacopeia.
- Press release article from: PR Newswire January 18, 2002 700+ words
...FRANCISCO, Calif. -- Eos Biotechnology, Inc. has announced...Affymetrix Inc., Aventis Pasteur, Biogen Corporation...Seattle Genetics. The Aventis Pasteur collaboration is...breast cancer. About Eos Biotechnology Eos Biotechnology...
- Eos Biotechnology Raises $27,500,000 In Private Financing to Fund Further...
- Press release article from: PR Newswire September 28, 2000 700+ words
...PRNewswire/ -- Eos Biotechnology, Inc. today announced...antibodies." Eos Biotechnology, a privately funded...cancer; and with Aventis-Pasteur for genome-derived...2302, both of Eos Biotechnology, Inc.; or Tom...
- Eos Biotechnology and Case Western Reserve University Receive $6.7 Million,...
- Press release article from: PR Newswire September 20, 2000 700+ words
...PRNewswire/ -- Eos Biotechnology, Inc. announced...development." Eos Biotechnology, a privately funded...cancers; and with Aventis-Pasteur for genome-derived...northern Ohio. Eos Biotechnology, Inc. David Mack...
- Eos Biotechnology and Biogen Announce Genomic Target & Therapeutic Antibody...
- Press release article from: PR Newswire September 13, 2000 700+ words
...Mass., Sept. 13 /PRNewswire/ -- Eos Biotechnology, Inc. and Biogen, Inc. (Nasdaq...care and management in the future." Eos Biotechnology, a privately funded biotechnology...treating certain cancers; and with Aventis-Pasteur for genome-derived targets against...